Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus Health Services' subsidiary, Optival Health Solutions Private Limited, received two drug license suspension orders from state drug control authorities. The first, from the Assistant Drugs Controller in Durg District (Chhattisgarh), suspends the license of the New Adarsh Nagar-Durg store for five days. The second, from the Assistant Director of Drugs Control Administration in Bangalore Circle-05 (Karnataka), suspends the license of the Udani Layout store for two days. Both orders were received on July 2, 2025, and were issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The combined potential revenue loss from these suspensions is approximately Rs 2.45 lakhs (Rs 0.85 lakhs + Rs 1.60 lakhs), which is negligible relative to the company's overall operations.
The financial impact is minimal — just about Rs 2.45 lakhs in potential lost revenue across two stores. This is a routine regulatory compliance matter under drug licensing rules and is unlikely to materially affect the company's financials or stock price.